Walgreens, a major U.S. pharmacy retailer, is set to go private as it struggles with weak business performance. The decision to cut its dividend and change strategies has not been well received by investors. The company’s sale to Sycamore Partners is expected to close in the second half of 2025, offering $11.45 per share to shareholders.

The move to private hands could help Walgreens make bolder decisions for a turnaround without the pressure of pleasing Wall Street. However, the stock’s value is currently trading just above the takeout price, limiting potential returns. The uncertain future of the business, including the potential sale of its medical clinic division, poses risks and challenges for investors.

Investors in Walgreens face uncertainty as the company prepares to leave the public market. The sale of its clinic business could offer additional upside, but the lack of a timeline or guaranteed price complicates the investment outlook. Aggressive investors may find value in this special situation, but long-term prospects remain unclear.

For more insights on potential investments, The Motley Fool’s expert analyst team has identified the top 10 stocks to buy now. Their recommendations have historically outperformed the market significantly, offering substantial returns for investors. Don’t miss out on the latest opportunities by joining Stock Advisor for exclusive access to the top picks in the market.

Reuben Gregg Brewer, author of the article, has no position in the stocks mentioned. The Motley Fool also has no position in the stocks discussed and maintains a disclosure policy.

Read more at Yahoo Finance: 3 Things You Need to Know if You Buy Walgreens Stock Today